doi: 10.1161/hy0102.100537
(Hypertension. 2002;39:99.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
N-Terminal Pro-Brain Natriuretic Peptide After Myocardial Infarction
A Marker Of Cardio-Renal Function
From the Klinik und Poliklinik für Innere Medizin II, Klinikum der Universität (A.L., C.H., G.A.J.R., H.S., S.H.), Regensburg, Germany; Integrated Health Care Solutions, F. Hoffmann-La Roche Ltd (J.T., M.B.), Basel, Switzerland; and GSF, Institut für Epidemiologie (H.L.), München-Neuherberg, Germany.
Correspondence to Dr A. Luchner, Klinik und Poliklinik für Innere Medizin II, Klinikum der Universität, F.J.-Strauss Allee 11, 93042 Regensburg, Germany. E-mail andreas.luchner{at}klinik.uni-regensburg.de
N-terminal pro-brain natriuretic peptide (NT-proBNP) is increased early after acute myocardial infarction. We assessed the relationship of NT-proBNP with left ventricular function and mass as well as with renal function, hemodynamic, and anthropometric variables in 625 outpatients in the chronic phase after myocardial infarction and 465 siblings without infarction (control). NT-proBNP was measured by nonextracted, enzyme-linked, sandwich immunoassay. NT-proBNP was correlated with left ventricular ejection fraction, mass index, and renal function, in addition to infarction history, gender, and age, in univariate and multivariate analysis (all P<0.01). Increases in NT-proBNP observed in subjects with infarction (96.6±13.7 versus 31.2±1.8 pmol/L in control subjects, P<0.001) were particularly pronounced in the presence of significant left ventricular dysfunction (182.8±41.9 pmol/L), left ventricular hypertrophy (214.5±61.7 pmol/L), and renal dysfunction (210.3±51.4 pmol/L, all P<0.01). Patients with an ejection fraction <35% were detected by NT-proBNP with a sensitivity, specificity, and negative predictive value of 75%, 62%, and 99%, respectively, at an optimal cutoff of 44 pmol/L. Patients with an ejection fraction <35% and concomitant left ventricular hypertrophy were detected with a sensitivity, specificity, and negative predictive value of 90%, 80%, and 99.9%, respectively, at a cutoff of 76 pmol/L. Similar results were obtained for patients with an ejection fraction <35% and concomitant renal dysfunction at a cutoff of 162 pmol/L. NT-proBNP is a biochemical marker of integrated cardio-renal function in the chronic phase after myocardial infarction and a potential diagnostic tool for the detection and exclusion of significant left ventricular dysfunction. Cutoff concentrations have to be chosen according to renal function to optimize the predictive value of NT-proBNP.
Key Words: natriuretic peptides • myocardial infarction • heart failure • renal disease
This article has been cited by other articles:
 |
|
 |
|
  M. Schou, F. Gustafsson, C. N. Kistorp, P. Corell, A. Kjaer, and P. R. Hildebrandt Effects of Body Mass Index and Age on N-Terminal Pro Brain Natriuretic Peptide Are Associated with Glomerular Filtration Rate in Chronic Heart Failure Patients Clin. Chem., November 1, 2007; 53(11): 1928 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-S. Spanaus, F. Kronenberg, E. Ritz, R. Schlapbach, D. Fliser, M. Hersberger, B. Kollerits, P. Konig, A. von Eckardstein, and for the Mild-to-Moderate Kidney Disease Study Grou B-Type Natriuretic Peptide Concentrations Predict the Progression of Nondiabetic Chronic Kidney Disease: The Mild-to-Moderate Kidney Disease Study Clin. Chem., July 1, 2007; 53(7): 1264 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R.J. van Kimmenade, J. L. Januzzi Jr, A. L. Baggish, J. G. Lainchbury, A. Bayes-Genis, A. M. Richards, and Y. M. Pinto Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure: Redefining the Cardiorenal Interaction? J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1621 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Norozi, R. Buchhorn, C. Kaiser, G. Hess, R. W. Grunewald, L. Binder, and A. Wessel Plasma N-Terminal Pro-Brain Natriuretic Peptide as a Marker of Right Ventricular Dysfunction in Patients With Tetralogy of Fallot After Surgical Repair Chest, October 1, 2005; 128(4): 2563 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Binder, B. Pieske, M. Olschewski, A. Geibel, B. Klostermann, C. Reiner, and S. Konstantinides N-Terminal Pro-Brain Natriuretic Peptide or Troponin Testing Followed by Echocardiography for Risk Stratification of Acute Pulmonary Embolism Circulation, September 13, 2005; 112(11): 1573 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mockel, R. Muller, J. O. Vollert, C. Muller, A. Carl, D. Peetz, F. Post, J. K. Kohse, and K. J. Lackner Role of N-Terminal Pro-B-Type Natriuretic Peptide in Risk Stratification in Patients Presenting in the Emergency Room Clin. Chem., September 1, 2005; 51(9): 1624 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Herrmann, I. Kindermann, S. Muller, T. Georg, M. Kindermann, M. Bohm, and W. Herrmann Relationship of Plasma Homocysteine with the Severity of Chronic Heart Failure Clin. Chem., August 1, 2005; 51(8): 1512 - 1515. [Full Text] [PDF]
|
|
|
|
|
|
D. Jefic, J. W. Lee, D. Jefic, R. T. Savoy-Moore, and H. S. Rosman Utility of B-Type Natriuretic Peptide and N-terminal Pro B-Type Natriuretic Peptide in Evaluation of Respiratory Failure in Critically Ill Patients Chest, July 1, 2005; 128(1): 288 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Luchner, C. Hengstenberg, H. Lowel, G. A.J. Riegger, H. Schunkert, and S. Holmer Effect of Compensated Renal Dysfunction on Approved Heart Failure Markers: Direct Comparison of Brain Natriuretic Peptide (BNP) and N-Terminal Pro-BNP Hypertension, July 1, 2005; 46(1): 118 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ala-Kopsala, H. Ruskoaho, J. Leppaluoto, L. Seres, R. Skoumal, M. Toth, F. Horkay, and O. Vuolteenaho Single Assay for Amino-Terminal Fragments of Cardiac A- and B-Type Natriuretic Peptides Clin. Chem., April 1, 2005; 51(4): 708 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schnabel, H. J. Rupprecht, K. J. Lackner, E. Lubos, C. Bickel, J. Meyer, T. Munzel, F. Cambien, L. Tiret, S. Blankenberg, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study Eur. Heart J., February 1, 2005; 26(3): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ala-Kopsala, J. Magga, K. Peuhkurinen, J. Leipala, H. Ruskoaho, J. Leppaluoto, and O. Vuolteenaho Molecular Heterogeneity Has a Major Impact on the Measurement of Circulating N-Terminal Fragments of A- and B-Type Natriuretic Peptides Clin. Chem., September 1, 2004; 50(9): 1576 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H.B. Wu, M. Packer, A. Smith, R. Bijou, D. Fink, J. Mair, L. Wallentin, N. Johnston, C. S. Feldcamp, D. M. Haverstick, et al. Analytical and Clinical Evaluation of the Bayer ADVIA Centaur Automated B-Type Natriuretic Peptide Assay in Patients with Heart Failure: A Multisite Study Clin. Chem., May 1, 2004; 50(5): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dasgupta, L. Chow, G. Tso, and L. Nazareno Stability of NT-proBNP in Serum Specimens Collected in Becton Dickinson Vacutainer (SST) Tubes Clin. Chem., June 1, 2003; 49(6): 958 - 960. [Full Text] [PDF]
|
|